Curated News
By: NewsRamp Editorial Staff
March 23, 2026
Soligenix Advances Orphan Drug Innovation with HyBryte™ for CTCL
TLDR
- Soligenix's HyBryte offers a competitive edge with faster response times and potential at-home treatment for cutaneous T-cell lymphoma, leveraging a de-risked orphan drug model.
- Soligenix's HyBryte uses visible light activation instead of chemotherapy, with a Phase 3 study set for interim analysis in early 2026 and top-line results later that year.
- Soligenix's approach improves patient safety and enables at-home treatment for rare diseases, making healthcare more accessible and effective for those with unmet medical needs.
- Soligenix's HyBryte therapy activates with visible light, a novel method that could expand to treat psoriasis and other conditions, funded by over $60 million in non-dilutive grants.
Impact - Why it Matters
This development matters because it addresses critical unmet needs in rare diseases like cutaneous T-cell lymphoma, where treatment options are limited and often carry significant side effects. HyBryte™'s visible light approach offers a safer, potentially more effective alternative to traditional therapies, with the added benefit of enabling at-home treatment through telehealth—improving accessibility and quality of life for patients. For the biopharmaceutical industry, Soligenix's de-risked model and use of non-dilutive funding could set a precedent for more sustainable orphan drug development, accelerating innovations in rare disease therapeutics. Additionally, the company's broader pipeline, including vaccines for public health threats, underscores its role in advancing both specialized and widespread medical solutions, impacting patient care and public health preparedness.
Summary
Soligenix (NASDAQ: SNGX) is pioneering a de-risked approach to orphan drug development, as highlighted in a recent citybiz feature, focusing on patient safety and capital efficiency. The company's lead candidate, HyBryte™, represents a breakthrough for cutaneous T-cell lymphoma (CTCL) patients by using visible light activation instead of traditional chemotherapy or UV-based therapies. Clinical data shows faster response times and a favorable safety profile, with potential for at-home treatment through telehealth-enabled delivery, offering new hope for those with this rare cancer.
The company is nearing completion of a confirmatory Phase 3 study for HyBryte™, with interim analysis expected in early 2026 and top-line results later that year. Soligenix leverages regulatory incentives for orphan diseases and over $60 million in non-dilutive funding to advance multiple pipeline candidates, including potential applications in psoriasis and autoimmune conditions. This positions the company for significant growth in rare disease therapeutics, supported by strong patient response rates and a differentiated development model.
Beyond its Specialized BioTherapeutics segment, Soligenix's Public Health Solutions business includes vaccine candidates for ricin toxin, filoviruses like Marburg and Ebola, and COVID-19 prevention using proprietary ThermoVax® technology. Supported by government funding from agencies like NIAID, DTRA, and BARDA, the company demonstrates a comprehensive approach to addressing unmet medical needs. For investors seeking updates, the latest news is available through the company's newsroom at BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN that provides extensive distribution and corporate communications solutions.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Advances Orphan Drug Innovation with HyBryte™ for CTCL
